Nautilus Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nautilus Biotechnology, Inc. (Nasdaq: NAUT) on September 11, 2026. The filing reports the entry into a new material definitive agreement and the termination of a prior agreement regarding an "at-the-market" equity offering program.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to raise up to $125,000,000 in aggregate sales proceeds through the new Sales Agreement.
Material Changes
- New Sales Agreement: On September 11, 2026, the Company entered into a Sales Agreement with TD Securities (USA), LLC ("TD Cowen") to sell shares of common stock via an "at-the-market" offering program.
- Termination of Prior Agreement: The Company mutually terminated its previous Sales Agreement with TD Cowen, dated February 28, 2024. No shares were sold under the prior agreement.
- Compensation: TD Cowen is entitled to compensation of up to 3.0% of the gross proceeds from shares sold under the new agreement.
- Flexibility: The Company retains the right to set sale parameters, suspend offers, or terminate the agreement with ten days' notice.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on operational outlook. The agreement includes a termination clause allowing for immediate termination in the event of a material adverse change in the Company. The sale of shares is contingent upon the effectiveness of the Company's shelf registration statement on Form S-3 filed on September 11, 2026.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 Registration Statement filed on September 11, 2026.
- Monitor future filings for actual share issuance volumes and proceeds generated under the new $125 million program.
- Review the Company's most recent 10-Q or 10-K for current cash position and burn rate to assess the necessity of this capital raise.
- Confirm the current trading price of NAUT to evaluate the potential dilution impact of the 3.0% sales agent commission.